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Abstract
A subset of myeloproliferative disorders (MPN) and myelodyplastic syndromes (MDS) evolves to fibrosis of the bone
marrow associated with haematopoietic insufficiency. We have been interested in chemokines involved in
fibrogenesis within the bone marrow. Besides TGFb we could identify a number of additional mediators including
osteoprotegerin and bone morphogenic proteins. In MPN JAK2 or MPL mutation are not linked to the propensity
for bone marrow fibrosis. The hypothesis that an increased intramedullary decay of megakaryocytes undergoing
appotosis takes place within the marrow, thus liberating fibrogenic cytokines, could not be confirmed. On the
contrary, megakaryocytes in primary fibrosis revealed low expression of proapoptotic genes such as BNIP3.
Interestingly, BNIP 3 expression was down regulated in megakaryocytic cell lines kept in hypoxic conditions.
Furthermore, expression arrays revealed hypoxia inducible genes to be up-regulated in primary myelofibrosis.
Fibrotic MPN are characterized by aberrant proplatelet formation which represent cytoplasmic pseudopodia and
normally extend into the sinus. In fibrotic MPN orientation of proplatelet growth appears to be disturbed, which
could lead to an aberrant deposition of platelets in the marrow with consecutive liberation of fibrogenic cytokines.
Introduction
Myeloproliferative Neoplasms (MPN) represent clonal
proliferations of pathological haematopoietic stem cell,
which have become independent from physiological
growth control but retain the ability to differentiate com-
pletely into all hematopoietic lineages. All or a subset of
the haematopoietic lineages can be affected, resulting in a
mono-, bi- or trilinear proliferation of megakaryocytic,
erythroid and granulocytic precursor cells. MPN encom-
pass chronic myeloid leukaemia (CML), polycythemia vera
(PV), essential thrombocythemia (ET) and primary myelo-
fibrosis (PMF). Chronic neutrophilic leukaemia (CNL) and
chronic eosinophilic leukaemia (CEL) represent rare forms
of MPN [1]. Although stable for a long period from years
to decades all MPN may progress to either blast crisis or
to bone marrow fibrosis. The propensity, however, to
develop these typical complications varies considerably
between the subtypes. Although the WHO classification
suggests that the fibrotic potential of MPN with predomi-
nant thrombocytosis such as ET and cellular PMF can be
differentiated on the ground of morphology alone, the few
prospective clinical trials which have been performed in
the field have suggested that this concept has to be ques-
tioned [2].
Therefore, molecular markers derived from a deeper
understanding of pathogenesis are necessary to achieve
a more accurate and reproducible classification of MPN
according to their risk of fibrotic progression.
Results and discussion
Chemokines involved in Fibrogenesis
Transforming growth factor beta-1 (TGF beta-1) is a
potent inducer of fibrosis and has been shown to be essen-
tial for the development of bone marrow fibrosis in an ani-
mal model of PMF [3]. Megakaryocytes and platelets have
been suggested as the major cellular source of TGF beta-1
in PMF. We analysed total bone marrow cells from bone
marrow trephines by PCR of cDNA, and found TGF beta-
1 mRNA expression to be increased in some but not all
cases of IMF (n = 21), with highest values in fibrotic cases
[4]. Unexpectedly, increased values were also observed in
essential thrombocythaemia (ET, n = 11) when compared
to non-neoplastic haematopoiesis (n = 38). Megakaryo-
cytes isolated by laser microdissection displayed elevated
TGF beta-1 mRNA levels in most of the MPN samples
with no significant differences discernible between fibrotic * Correspondence: Kreipe.Hans@MH-Hannover.de
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was predominantly expressed by the myeloid lineage in
Ph-negative MPN and non-neoplastic haematopoiesis,
which, however, displayed lower expression. Thus,
enhanced TGF beta-1 expression occurs in megakaryo-
cytes as well as myeloid cells in Ph-negative MPN. TGF
beta-1 may be necessary, but is not sufficient, to induce
bone marrow fibrosis in PMF because non-fibrotic Ph-
negative MPN entities share this feature with PMF and
cannot be discriminated from each other on the basis of
TGF beta-1 expression. Among the cytokines which we
found to be increased in fibrotic MPN were PDGF [5] and
FGF [6] but a strict correlation to fibrosis could not be
established in either case because also ET demonstrated
overexpression.
Advanced myelofibrosis with osteosclerosis and increase
and thickening of bone trabeculae is typically contrasted
by the absence or sparse presence of osteoclasts. Because
osteoclast formation can be inhibited by osteoprotegerin
(OPG) we investigated OPG expression in PMF with
severe fibrosis and osteosclerosis, which expressed signifi-
cantly higher (up to 71-fold) OPG mRNA levels when
compared with prefibrotic cellular PMF and control cases.
The receptor activator of nuclear factor kappaB ligand
(RANKL), a positive regulator of osteoclast differentiation
and putative antagonist of OPG was overexpressed by up
to 34-fold exclusively in advanced PMF. Case-specific cal-
culation of the RANKL/OPG ratio in advanced PMF
showed a wide range without significant differences when
compared with the prefibrotic PMF and non-neoplastic
haematopoiesis. Immunohistochemical detection of OPG
protein revealed strong labelling of endothelial cells within
proliferating vessels in fibrotic PMF and heterogeneously
labelled megakaryocytes, and fibroblasts. Osteosclerosis
and impaired osteoclast fun c t i o ni nP M Fa p p e a r st ob e
associated with upregulated endothelial OPG expression
but concomitant reduction of the antagonist RANKL
could not be demonstrated. It appears, that osteosclerosis
in PMF is associated with increased endothelial OPG
expression without concomitant RANKL downregulation
[7].
The involvement of members of the bone morphogenetic
protein (BMP) family in aberrant bone marrow matrix
homeostasis in PMF has not yet been investigated. There-
fore, we analyzed expression of BMP1, an activator of
latent transforming growth factor beta-1 (TGFbeta-1) and
processor of collagen precursors, and other BMPs in bone
marrow from PMF patients and controls (n = 95). Expres-
sion of BMP1, BMP6, BMP7, and BMP-receptor 2 was sig-
nificantly increased in advanced stages of myelofibrosis
compared with controls (P < or = 0.01), and enhanced
levels of BMP6 expression were already evident in prefibro-
tic stages of PMF. Immunohistochemistry showed that
bone marrow stromal cells and megakaryocytes were the
major cellular sources of BMP1 protein. Because TGFbeta-
1 and basic fibroblast growth factor have been shown to be
important in the development of myelofibrosis, we studied
the induction of BMPs by these cytokines in cultured fibro-
blasts. Fibroblasts treated with TGFbeta-1 showed a pro-
nounced up-regulation of BMP6, suggesting that stromal
cells may be susceptible to BMP activation by cytokines
with a proven role in the pathogenesis of PMF. We con-
clude that BMP family members may play an important
role in the pathogenesis of myelofibrosis in PMF and are
apparently induced by cytokines such as TGFbeta-1 [8].
Role of JAK2 and MPL
Although the cellular phase of PMF has been demon-
strated to represent a clonal disease [9], it shares with all
other Ph- MPN the peculiar phenomenon that only a
proportion of cells is affected by JAK2 or MPL mutation
[10]. We have been interested whether in follow-up biop-
sies from MPN patient an increase in allele burden was
associated with increased fiber deposition and whether
ET differs from cellular PMF. Histopathology of 490
MPN cases was correlated with the allelic burden of
JAK2(V617F) and MPL(W515L) [11]. Ph-negative MPN
entities largely overlap with regard to JAK2(V617F) and
M P L ( W 5 1 5 L )a l l e l eb u r d e n ,b u tE Td i s p l a y e dm u t a n t
allele burden <50%. PMF with different stages of myelofi-
brosis all yielded similar JAK2(V617F) allele burden. At
initial presentation one-quarter of prefibrotic PMF cases
exhibited an allele burden exceeding 50% (38% median
JAK2(V617F) alleles, n = 102). In ET, its main differential
diagnosis, not a single case was found with >40% JAK2
(V617F) alleles (median, 24% JAK2(V617F) alleles; n =
90; p < 0.001). Increase in JAK2(V617F) alleles during
follow-up could not be linked to fibrosis or blastic pro-
gression but was related to polycythemic transformation
in ET. MPL(W515L) was found in 3% of ET and 8% of
PMF, with a significantly higher percentage of mutated
alleles in fibrotic than prefibrotic PMF (median, 78%
MPL(W515L) alleles; p < 0.05). Consequently, typical his-
tological findings in ET and prefibrotic PMF correlate
with significant differences in mutant allelic burden of
JAK2(V617F), but not of MPL(W515L). By contrast to
JAK2(V617F), MPL (W515L) shows a higher percentage
of mutated alleles in fibrotic than in prefibrotic cases. In
Ph-negative MPN with the differential diagnosis between
ET and prefibrotic PMF, a JAK2(V617F) allele burden
>50% favors a diagnosis of prefibrotic PMF. This does,
however, not imply that JAK2 allele burden is linked to
development of fibrosis in individual cases, because allelic
burden stayed stable during progression [12].
In a next step we evaluated whether differences between
JAK2 mutated and unmutated MPN cases with fibrosis
could be established. Because the JAK-STAT signaling
pathway is involved in the regulation of genes encoding
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fibrosis most likely represents an imbalance between
synthesis and turnover of collagen fibers, we hypothesized
that differences exist between mutated and unmutated
cases. The expression of MMPs, their tissue inhibitors
(TIMPs), and collagen types in relation to the JAK2 status
(V617F mutation versus wild-type) were studied in cellular
PMF (n = 64). Whereas no correlation was found between
the JAK2 status and MMP gene products, there was an
evident association with the stage of disease. Membrane
type 1-MMP (MMP-14) was overexpressed by up to 80-
fold in advanced stages that progressed to fibrosis (P <
0.001), and megakaryocytes and endothelial cells were
unmasked as the major cellular source. By contrast, a sig-
nificantly higher expression of neutrophil collagenase
(MMP-8) was encountered in the prefibrotic stages of
cIMF (P < 0.001). Altogether, the stepwise progress of
myelofibrosis in cIMF was associated with expression of a
defined subset of target genes as shown in sequential tre-
phine biopsies of cIMF patients. Obviously, the expression
of matrix-modeling genes in cIMF is not influenced by the
JAK2 mutation status but is predominantly related to the
stage of disease [12].
Intramedullary apoptosis of megakaryocytes
It has been speculated that an increase of megakaryocytic
decay and apoptosis in the bone marrow of MPN may
lead to an enhanced liberation of cytokines with a fibro-
genic potential [13]. In order to identify factors involved
in the aberrantly regulated apoptosis of megakaryocytes
in primary myelofibrosis (PMF), the mRNA expression of
human megakaryocytes in the bone marrow of PMF was
quantified by real-time polymerase chain reaction low-
density arrays. The mRNA from 200 to 300 laser-micro-
dissected megakaryocytes per case from PMF (n = 22)
and control (n = 10) bone marrow was reverse-tran-
scribed into cDNA by random priming and subsequently
amplified by primer-specific cDNA amplification. The
mRNA of corresponding total bone marrow cells was
reverse-transcribed into cDNA without the following
amplification. For relative mRNA quantification, custom-
made TaqMan low-density arrays with a setup of 48 dif-
ferent genes were applied. In addition, methylation analy-
sis and immunohistochemistry of a selected candidate
gene were accomplished. A trend toward an overall
downregulation of apoptosis-associated genes could be
observed in megakaryocytes, whereas the total bone mar-
row cellularity exhibited an overall upregulation of these
factors. Among several candidates with statistically signif-
icant deregulation BCL2/adenovirus E1B 19 kDa interact-
ing protein 3 (BNIP3) and protein kinase C beta1 were
shown to be the most aberrantly expressed genes. Apop-
tosis-related gene expression profiling of human mega-
karyocytes reveals a set of candidates, most notably
BNIP3, indicating that the increase of megakaryocytes in
myeloproliferative neoplasia might not only be the result
of increased proliferation but also of disturbed apoptosis
[14]. Thus megakaryocytes in PMF exhibit rather a
decrease of apoptosis than an increase and an exagger-
ated apoptotic decay as a source of fibrogenic cytokines
does not take place.
Potential role of hypoxia
When studying gene expression in PMF we encountered
an increased expression of genes related to hypoxia. We
investigated bone marrow core biopsies in PMF showing
various degrees of myelofibrosis by custom-made low den-
sity arrays (LDA) representing target genes with desig-
nated roles in synthesis of extracellular matrix, matrix
remodelling, cellular adhesion and motility. Among a set
of 11 genes up-regulated in advanced stages of PMF (P <
or = 0.01) three candidates, PTK2 protein tyrosine kinase
2 (PTK2), transforming growth factor beta type II receptor
(TGFBR2) and motility-related protein-1 (CD9 molecule,
CD9), were investigated in more detail. PTK2, TGFBR2
and CD9 were significantly overexpressed in larger series
of advanced PMF stages (P < or = 0.01 respectively).
Endothelial cells of the increased microvessel network in
PMF could be identified as a predominant source for
PTK2, TGFBR2 and CD9. CD9 also strongly identified
activated fibroblasts in advanced myelofibrosis [15]. As
CD9 expression is induced by hypoxia and angiogenesis is
a prominent feature in PMF hypoxia emerges as a poten-
tial regulator of bone marrow fibrosis.
Increased proplatelet formation in PMF
Although megakaryocytes have been identified as the
source of thrombocytes more than 100 years ago there is
still no consensus for how platelets are assembled.
Besides the cytoplasmic fragmentation model there is the
proplatelet model which is based on long cytoplasmic
extensions observed in megakaryocytes in vivo [3] and in
vitro. Pseudopodial cytoplasmic extensions of megakar-
yocytes according to this model provide the essential
intermediate structure for the generation of platelets.
The cytoplasmic extensions can reach 500 μmi nl e n g t h
and are presumed to get into contact with sinuses for the
release of platelets into the blood stream [16]. Proplate-
lets are usually not obvious in conventional bone marrow
histology and they may escape immunohistochemical
detection by the most frequently used megakaryocytic
markers factor VIII-related antigen and CD61. We have
visualized proplatelet formation in MPN in situ by
immunohistochemical detection of glycoprotein Ib (pla-
telet) alpha polypeptide (GP1BA; CD42). The expression
of GPIX, heterodimer complex with GP1B and GPV, in
the platelet membrane characterized an early differentia-
tion. Immunohistochemical stainings were evaluated by
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trephines from essential thrombocythaemia (ET, n = 10),
fibrotic (n = 10) and prefibrotic (n = 10) primary myelofi-
brosis (PMF) there was a significant increase of proplate-
let density compared with normal bone marrow samples
(n = 10; p < 0.001). Manifest fibrosis exhibited the high-
est density and volume ratio with significant differences
to non-fibrotic PMF (p < 0.001) and ET (p < 0.001). We
could demonstrate that besides megakaryocytic prolifera-
tion extensive pseudopodial proplatelet formation pro-
vides a hallmark of MPN. Obviously fibrosing differ from
non-fibrosing MPN by density and size of aberrant pro-
platelets [17].
The exaggerated proplatelet formation appears to be
associated with an increased production of thrombospo-
din. Thrombospondins (TSP) are factors sharing pro-
fibrotic and anti-angiogenic properties, which have yet not
been studied in PMF before. We investigated the expres-
sion of TSP-1 and TSP-2 in PMF related to the stage of
myelofibrosis (n = 51) and in individual follow-up biopsies
by real-time PCR, immunohistochemistry, and confocal
laser scanning microscopy (CLSM). TSP-1 was signifi-
cantly overexpressed (p < 0.05) in all stages of PMF when
compared to controls. Individual follow-up biopsies
showed involvement of TSP-1 during progressive myelofi-
brosis. TSP-2 was barely detectable but 40% of cases with
advanced myelofibrosis showed a strong expression.
Megakaryocytes and interstitial proplatelet formations
were shown to be the relevant source for TSP-1 in PMF.
Stromal cells like endothelial cells and fibroblasts showed
no TSP-1 labeling when double-immunofluorescence
staining and CLSM were applied. Based on its dual
Figure 1 A-F: Immunohistochemistry for CD42b in ET (A, B), prefibrotic PMF mf0 (C, D) and fibrotic PMF (E, F).C o n f o c a ll a s e r
microscopy reveals dendritic processes (B, D, F; green staining) whereas in conventional immunohistochemistry predominantly cross sections are
seen (brown staining) which increase in density in fibrotic PMF (CD42b; ×400) [17].
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pro-fibrotic environment which discriminates PMF from
ET cases. On the other hand, TSP-1 is a factor acting
(ineffectively) against exaggerated angiogenesis. Both fea-
tures suggest TSP-1 to be a biomarker for monitoring a
PMF-targeted therapy. The higher number of proplatelets
in PMF is most likely responsible for the increase of
thrombospodin expression in comparison to ET.
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